Taiwan's Academia Sinica announced that a group of its researchers has developed a two-terminal (2T) perovskite-silicon tandem solar cell with a power conversion efficiency of 31.5%.

Novel therapies targeting molecular pathways, including DLL3 and PARP inhibitors, show promise in improving SCLC survival outcomes. Tarlatamab, a DLL3-targeting bispecific T-cell engager ...

To anyone who has spent some time in photovoltaic (PV) power circles, the word ‘perovskite’ probably sounds familiar. Offering arguably better bandgap properties than traditional silicon cells ...

The team has developed a novel method for the remote epitaxial growth of continuous crystalline perovskite thin films. This advance allows for seamless integration into ultrahigh-resolution micro ...

Researchers at South Korea’s Ulsan National Institute of Science and Technology (UNIST) claim to have achieved a power conversion efficiency of 25.8% for a single junction perovskite solar cell ...

This approval establishes serplulimab as the first and only anti-PD-1 mAb approved in the EU for the treatment of ES-SCLC. Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius ...